conference logo
 
Programme  Titles  Presenters  Topics 
Session 4 - High Grade Glioma
Thursday, May 7, 1:15pm - 2:25pm

MODERATORS: Anat Erdreich-Epstein, Will Parsons

 


HG-08 Disrupting the epigenetic modifier HMGA2 in DIPG and GBM inhibits tumor invasion, growth and tumorigenicity
Harpreet Kaur*, Marianne Hütt-Cabezas, Isabella Taylor, Melanie Weingart, Fausto Rodriguez, Charles Eberhart, Eric Raabe
The Johns Hopkins Hospital, USA
HG-02 ATRX loss promotes tumor growth and impairs genetic stability in glioblastoma
Carl Koschmann*1, Alexandra Calinescu1, Daniel Thomas1, Felipe J. Nunez1, Marta Dzaman1, Johnny Krasinkiewicz1, Neha Kamran1, Rosie Lemons1, Flor Mendez1, Youping Li1, David Ferguson1, Vera Gorbunova3, Soyeon Roh1, Lili Zhao1, Alan Meeker2, Pedro R. Lowenstein1, Maria G. Castro1
1University of Michigan, USA, 2Johns Hopkins University, USA, 3University of Rochester, USA
PM-13 Biological consequences of histone mutations in the mammalian brain
Jon Larson*, Lawryn Kasper, Helen Russell, Chunxu Qu, Xiaoyan Zhu, Peter McKinnon, Suzanne Baker
St. Jude Children's Research Hospital, USA
OT-05 H3.3-K27M is a negative prognostic marker in thalamic pediatric glioma
Scott Ryall*1,2, Pawel Buczkowicz1, Rahul Krishnatry1, Anthony Arnoldo1, Paul Steinbok3,4, Uri Tabori1,2, Cynthia Hawkins1,2
1Hospital for Sick Children, Canada, 2University of Toronto, Canada, 3BC Children's Hospital, Canada, 4University of British Columbia, Canada
HG-11 Integrative molecular meta-analysis of 700 pediatric high grade glioma and DIPG defines widespread inter- and intra-tumoral heterogeneity
Alan Mackay*1, Mara Vinci1, Anna Burford1, Lynn Bjerke1, Katy Taylor1, Meera Nandhabalan1, Lynley Marshall1, Valeria Molinari1, Sergey Popov1, Wendy Ingram2, Andrew Moore2, Saoussen Trabelsi3, Dorra Hmida3, Kun Mu4, Lucas Bidinotto5, Rui Reis5, HK Ng6, Andre von Bueren7, Michael Baudis8, Chris Jones1
1Institute of Cancer Research, UK, 2Queensland Childrens Medical research Institute, Australia, 3CHU Farhat HACHED, Tunisia, 4Qilu Hospital, China, 5Barretos Cancer Hospital, Brazil, 6Chinese University of Hong Kong, Hong Kong, 7University of Goettingen, Germany, 8University of Zurich, Switzerland
IM-02 A scFv-based CAR to redirect T cells to IL13Rα2-positive pediatric glioma
Giedre Krenciute*1, Simone Krebs1, David Torres1, Maciej Lesniak2, Irina Balyasnikova2, Stephen Gottschalk1
1Baylor College of Medicine, USA, 2University of Chicago, USA
TR-14 A feasibility and randomized phase II study of vorinostat, bevacizumab, or temozolomide during radiation followed by maintenance chemotherapy in newly-diagnosed pediatric high-grade glioma: Children’s Oncology Group study ACNS0822
Lindsey M. Hoffman*1, James Geller1, James Leach1, Daniel Boue2, Rachid Drissi1, Lu Chen3, Mark Krailo3, Atmaram Pai Panandiker4, Lionel Chow1, Daphne Haas-Kogan5, Sachin Jogal6, Marvin Nelson7, Reggie Jakacki9, Mark Kieran8, Kenneth Cohen10, Ian Pollack9, Amar Gajjar4, Maryam Fouladi1
1Cincinnati Children's Hospital Medical Center, USA, 2Dayton Children's Hospital, USA, 3Children's Oncology Group Statistics and Data Center, USA, 4St. Jude Children's Hospital Medical Center, USA, 5University of California San Francisco, USA, 6Midwest Children's Cancer Center, USA, 7Children's Hospital of Los Angeles, USA, 8Dana-Farber Cancer Institute, USA, 9Children's Hospital of Pittsburg, USA, 10Johns Hopkins University/Sidney Kimmel Cancer Center, USA